Copper Gluconate

證據等級: L5

預測適應症: 0 個

Copper Gluconate: Drug Repurposing Assessment — No TxGNN Prediction Available

One-Sentence Summary

Copper gluconate is a copper salt used as a dietary mineral supplement and therapeutic agent for copper deficiency. The TxGNN model was unable to generate any repurposing prediction for this compound due to an unresolved DrugBank identifier and the absence of any SAHPRA-registered product in the pipeline. This report documents the current data gaps and the remediation steps required before a formal repurposing evaluation can proceed.

Quick Overview

Item	Content
Original Indication	Not documented in current data
Predicted New Indication	None — TxGNN prediction not generated
TxGNN Prediction Score	N/A
Evidence Level	N/A — No prediction generated
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why No Prediction Was Generated

The TxGNN knowledge graph pipeline requires a valid DrugBank ID to anchor a compound within the disease–drug network and generate ranked repurposing candidates. For Copper Gluconate, the DrugBank query returned one result (result_count: 1), yet the drugbank_id field remains unresolved (null). This indicates the compound may be catalogued under a related identifier — for example, elemental copper (DrugBank: DB09130) or under a specific salt or formulation entry — that the automated matching step did not confirm.

Additionally, no SAHPRA-registered product was found (0 licences), and no original approved indications are on record within the current dataset. Without these regulatory anchors, the pipeline lacks the inputs needed to generate a meaningful disease ranking.

Two critical data gaps are blocking progress:

Gap ID	Missing Item	Severity	Downstream Impact
DG001	Regulatory warnings and contraindications	Blocking	Cannot complete safety pre-screening (S1 gate)
DG002	Mechanism of action (MOA)	High	Cannot perform mechanistic relevance analysis or pathway mapping

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA at www.sahpra.org.za.

Conclusion and Next Steps

Decision: Hold

Rationale: No TxGNN repurposing prediction was generated for Copper Gluconate because the DrugBank ID could not be resolved and no SAHPRA regulatory data is available. Until the knowledge graph anchor is confirmed and the blocking safety data gap is remediated, the evidence pipeline cannot produce a reviewable output.

To proceed, the following is needed:

Resolve the DrugBank ID: Manually verify whether Copper Gluconate maps to DrugBank DB09130 (“Copper”) or a distinct salt-specific entry; update the pipeline input with the confirmed identifier before re-running.
Retrieve MOA data (DG002): Once the DrugBank ID is confirmed, query the DrugBank API to extract mechanism of action, pharmacological targets, and enzyme pathway data.
Obtain safety data (DG001): Locate and parse the relevant Professional Information (PI) document to populate warnings, contraindications, and drug-drug interaction fields — this is a blocking requirement before any safety gate can be passed.
Verify SAHPRA registration status: Check whether any product containing Copper Gluconate (e.g., as a supplement ingredient or combination product) holds an active SAHPRA licence; update the regulatory record accordingly.
Re-run TxGNN prediction: Once all inputs above are in place, resubmit a corrected Evidence Pack to generate candidate disease predictions and a scoreable output.

⚠️ Disclaimer: This report is for research reference purposes only and does not constitute medical advice. Any drug repurposing candidate identified by TxGNN requires clinical validation before application. All findings should be interpreted in conjunction with SAHPRA-approved product information and relevant clinical guidelines.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.